Posted by Michael Wonder on 22 Jun 2023
PHARMAC considers widening access to treatments for multiple sclerosis and haemophilia A
22 June 2023 - PHARMAC has started a consultation today for widening access for two treatments; ocrelizumab (Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (Hemlibra) for the treatment of all people with severe haemophilia A.
“Ocrelizumab and emicizumab have been on our options for investment list as medicines we would like to fund for these conditions, so we are pleased we have secured the provisional agreement with their supplier, Roche,” concludes Ms MacGibbon.
